Together, the literature suggests that IQGAP1 could be a valuable therapeutic target in treating patients with pancreatic cancer, potentially even those patients with cancers that display intrinsic/acquired drug resistance. Here, IQGAP1 is linked to familial pancreatic carcinoma.